Published in Clinical Trials Week, May 21st, 2007
"Our clinical objectives for 2007 include the completion of our ongoing proof-of-concept trials for MEM 1003 and MEM 3454, and we've made good progress during the first quarter of 2007 toward achieving these objectives," said Jim Sulat, President and Chief Executive Officer. "Since the beginning of the year, we've initiated our Phase 2a Alzheimer's disease trial for MEM 3454, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.